Mirae Asset Global Investments Co., Ltd. Corvus Pharmaceuticals, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $28 Billion
- Q2 2025
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 2,979 shares of CRVS stock, worth $22,729. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,979
Previous 2,048
45.46%
Holding current value
$22,729
Previous $6,000
83.33%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CRVS
# of Institutions
102Shares Held
38.9MCall Options Held
98.5KPut Options Held
226K-
Orbimed Advisors LLC San Diego, CA7.17MShares$54.7 Million1.02% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct7.04MShares$53.7 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.28MShares$25 Million0.0% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$25 Million9.69% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$20.4 Million0.16% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $355M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...